Reorganisation starts in the Angelini Group: Marullo di Condojanni also pharma CEO
The aim is to maximise focus on the two core businesses, Pharma and Technologies, and optimise organisational complexity
3' min read
3' min read
Sergio Marullo di Condojanni will be the new CEO of Angelini Pharma from next January and will retain the position of ceo of Angelini industries, whose mandate and perimeter will be reduced to a strategic scope and financial allocation of resources. In the Angelini group, the countdown has started that will lead to the reorganisation of the parent company, Angelini Holding, and Angelini Pharma, the main operations. From an organisational point of view, Angelini Holding will reorient its mandate from industrial holding company to holding portfolio of participations and investments with strategic, financial and control purposes. Operational activities will be delegated entirely to the subsidiaries, which will be enriched with skills and expertise that are currently the prerogative of the parent company, simplifying the organisational structure and speeding up decision-making processes. Angelini Industries employs about 5,600 employees and operates in 21 countries worldwide with revenues that in the 2024 financial statements, the first one prepared in compliance with IFRS (International Financial Reporting Standards), amounted to 1.6 billion euros, up 3% compared to 2023 (they would have been more than 2.2 billion euros according to the accounting standards previously applied). 77% of the revenues are generated by the health area and the reorganisation will close a five-year cycle during which all businesses have been strengthened and conditions created for their growth and sustainability over time.
The passing of the baton
.The current ceo of Angelini Pharma, Jacopo Andreose - who hands over the baton to Marullo di Condojanni - will continue his path in the group, as a member of the board of Angelini holding and senior advisor to the board of Angelini Pharma. The move is in line with the company's long-term strategy, in which inorganic growth operations will be central and for which direct shareholder commitment is fundamental.
The two main businesses
."The reorganisation is functional to greater decision-making autonomy and executive effectiveness of the operating companies necessary to continue to grow our two main businesses, pharma and industrial technology," explains Marullo di Condojanni. Instead, the holding company will be more focused on a key role of strategy and financial allocation'. The objective, adds the manager, "is therefore on the one hand that of long-term competitiveness in the sectors in which we are present, and on the other hand that of seizing opportunities for potential M&A operations that, provided we are still in control as majority shareholders, will allow us, particularly in pharma, to create a transformative deal that will enable us to operate on a broader scale".
The reorganisation of the two entities is functional to the strategy of focus and development that Angelini is pursuing in its two main businesses. On one side there is in fact Angelini Pharma, already committed to an ambitious growth plan, to strengthen its presence in international markets and to evolve its portfolio also through extraordinary operations. On the other is Angelini Technologies - Fameccanica, increasingly oriented towards a path of expansion into foreign markets and diversification. At the centre of the strategy is also the enhancement of Italian assets, with a particular focus on Research and Development and production plants.
Pharma's breakthrough
.For Angelini Pharma, the new operating model will represent a further step forward in order to compete more effectively in the markets, pursuing a strategy of growth through internal and external lines aimed at creating a player of scale, capable of competing on a global level. Angelini Pharma's new structure envisages the establishment of franchises dedicated to the main business areas - Consumer Healthcare and Central Nervous System - in order to maximise the Group's assets. Then there will be the strengthening of corporate strategy and business development skills to support M& A operations and international expansion, and the strengthening of the Global Medical Department, even more focused on the development of scientific leadership.
